ATE183184T1 - Neuroprotektive chroman verbindungen - Google Patents

Neuroprotektive chroman verbindungen

Info

Publication number
ATE183184T1
ATE183184T1 AT94931668T AT94931668T ATE183184T1 AT E183184 T1 ATE183184 T1 AT E183184T1 AT 94931668 T AT94931668 T AT 94931668T AT 94931668 T AT94931668 T AT 94931668T AT E183184 T1 ATE183184 T1 AT E183184T1
Authority
AT
Austria
Prior art keywords
pct
neuroprotective
sec
date
chrome compounds
Prior art date
Application number
AT94931668T
Other languages
English (en)
Inventor
Todd W Butler
Bertrand L Chenard
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE183184T1 publication Critical patent/ATE183184T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94931668T 1994-01-31 1994-11-21 Neuroprotektive chroman verbindungen ATE183184T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18947994A 1994-01-31 1994-01-31

Publications (1)

Publication Number Publication Date
ATE183184T1 true ATE183184T1 (de) 1999-08-15

Family

ID=22697514

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94931668T ATE183184T1 (de) 1994-01-31 1994-11-21 Neuroprotektive chroman verbindungen

Country Status (27)

Country Link
US (1) US5744483A (de)
EP (1) EP0741724B1 (de)
JP (1) JP2866743B2 (de)
CN (1) CN1048247C (de)
AT (1) ATE183184T1 (de)
AU (1) AU684568B2 (de)
BR (2) BR9408506A (de)
CA (1) CA2182101C (de)
CO (1) CO4230161A1 (de)
CZ (1) CZ286757B6 (de)
DE (1) DE69420053T2 (de)
DK (1) DK0741724T3 (de)
EG (1) EG20672A (de)
ES (1) ES2134361T3 (de)
FI (1) FI113769B (de)
GR (1) GR3031356T3 (de)
HU (1) HU221633B1 (de)
IL (1) IL112415A (de)
MY (1) MY111623A (de)
NO (1) NO309190B1 (de)
NZ (1) NZ275151A (de)
PE (1) PE43795A1 (de)
PL (1) PL179448B1 (de)
RU (1) RU2126404C1 (de)
TW (1) TW449591B (de)
WO (1) WO1995020587A1 (de)
ZA (1) ZA95692B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0859773A1 (de) * 1995-09-15 1998-08-26 Pfizer Inc. Phenol derivate mit pharmazeutischen wirkung
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
EP1674087A1 (de) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylaktische Verwendung von N-Methyl-D-Aspartat Rezeptor (NMDA) Antagonisten
ZA200108038B (en) * 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
BRPI0618206A2 (pt) 2005-11-03 2011-08-23 Hoffmann La Roche arilsulfonil cromanos como inibidores de 5-ht6, bem como composição farmacêutica, uso e processo para produção dos mesmos
WO2007084595A2 (en) * 2006-01-20 2007-07-26 Schering Corporation Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors
EP2522647B1 (de) * 2011-05-10 2014-04-30 DSM IP Assets B.V. Verfahren zum Trennen von chiralen Isomeren von Chromverbindungen und ihre Derivate und Vorläufer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3294804A (en) * 1961-01-27 1966-12-27 Sterling Drug Inc 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine
FR5733M (de) * 1966-09-27 1968-01-22
GB1495526A (en) * 1974-05-31 1977-12-21 Beecham Group Ltd Chroman derivatives
US4016281A (en) * 1975-02-22 1977-04-05 Merck Patent Gesellschaft Mit Beschrankter Haftung Tetralone and indanone compounds
US4082755A (en) * 1977-02-14 1978-04-04 Janssen Pharmaceutica N.V. 1-[(Diarylmethyl)aminoalkyl]piperidimes
WO1980000152A1 (en) * 1978-07-03 1980-02-07 Sandoz Ag 3-aminopropoxy-aryl derivates,preparation and use thereof
US4358456A (en) * 1980-05-03 1982-11-09 John Wyeth & Brother Limited Antipsychotic piperidinomethyl-indole derivatives
DE3045688A1 (de) * 1980-12-04 1982-07-08 C.H. Boehringer Sohn, 6507 Ingelheim Neue 8-arylalkyl-3-phenyl-3-nortropanole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung
GB2107706A (en) * 1981-09-25 1983-05-05 Beecham Group Plc Benzopyrans
EP0093534A1 (de) * 1982-04-28 1983-11-09 Beecham Group Plc Chromanolen
GB8308064D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds
FR2581993B1 (fr) * 1985-05-14 1988-03-18 Synthelabo Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
US4957928A (en) * 1986-06-26 1990-09-18 Ciba-Geigy Corporation Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
US4968678A (en) * 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US4968878A (en) * 1989-02-07 1990-11-06 Transitions Research Corporation Dual bumper-light curtain obstacle detection sensor
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
SK232890A3 (en) * 1989-05-17 1998-11-04 Pfizer 2-piperidino and 2-pyrrolidino-1-alkanols derivatives and preparation method thereof
HU222726B1 (hu) * 1990-02-06 2003-09-29 Pfizer, Inc., Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Also Published As

Publication number Publication date
RU2126404C1 (ru) 1999-02-20
CN1142825A (zh) 1997-02-12
CA2182101A1 (en) 1995-08-03
EP0741724B1 (de) 1999-08-11
NO963186D0 (no) 1996-07-30
HU9602100D0 (en) 1996-09-30
AU684568B2 (en) 1997-12-18
CZ225696A3 (en) 1997-01-15
CA2182101C (en) 1999-08-03
US5744483A (en) 1998-04-28
WO1995020587A1 (en) 1995-08-03
DE69420053D1 (de) 1999-09-16
DE69420053T2 (de) 1999-11-25
NO963186L (no) 1996-07-30
FI113769B (fi) 2004-06-15
NO309190B1 (no) 2000-12-27
PL179448B1 (pl) 2000-09-29
FI950403A0 (fi) 1995-01-30
PL315681A1 (en) 1996-11-25
DK0741724T3 (da) 1999-12-20
EP0741724A1 (de) 1996-11-13
CO4230161A1 (es) 1995-10-19
HU221633B1 (hu) 2002-12-28
JPH09501698A (ja) 1997-02-18
FI950403A (fi) 1995-08-01
TW449591B (en) 2001-08-11
ES2134361T3 (es) 1999-10-01
ZA95692B (en) 1996-07-30
JP2866743B2 (ja) 1999-03-08
IL112415A (en) 1999-07-14
AU8066394A (en) 1995-08-15
CN1048247C (zh) 2000-01-12
IL112415A0 (en) 1995-03-30
EG20672A (en) 1999-11-30
NZ275151A (en) 1998-02-26
PE43795A1 (es) 1995-12-09
CZ286757B6 (en) 2000-06-14
HUT75942A (en) 1997-05-28
BR9408506A (pt) 1997-08-05
BR9500380A (pt) 1995-10-17
MY111623A (en) 2000-09-27
GR3031356T3 (en) 2000-01-31

Similar Documents

Publication Publication Date Title
DE69523169D1 (de) Verwendung von Mangiferin oder seinen Derivaten zur kosmetischen Anwendung
UA49869C2 (uk) Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора
NO952890D0 (no) Kombinasjonsbehandling for inhibisjon av bentap
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
ATE183184T1 (de) Neuroprotektive chroman verbindungen
DK0946162T3 (da) Anvendelse af p-aminophenol-derivater til fremstilling af farmaceutiske præparater, som er nyttige til behandlingen af neurodegenerative sygdomme
DE69612510D1 (de) Verwendung von 1-(2-naphtylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin zur herstellung eines medikaments zur behandlung der amyotrophen lateralsklerode
DE69516110D1 (de) Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
NO20012310L (no) Optisk aktiv pyridyl-4H-1,2,4-oksazdiazinderivat og dets anvendelse ved behandling av karsykdommer
EP0653936A1 (de) Verwendung von 2-[4-(-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphtoquinon zur behandlung von krebs.
NZ268914A (en) Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease
ATE168697T1 (de) Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen
FR2804867B1 (fr) Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee